No Data
No Data
2seventy Bio: Buy Rating Amidst Challenges and Growth Potential in BCMA CAR-T Therapy
2seventy Bio (TSVT) Gets a Hold From Morgan Stanley
Insider Sale: Director at $TSVT (TSVT) Sells 3,900 Shares
US$8.25: That's What Analysts Think 2seventy Bio, Inc. (NASDAQ:TSVT) Is Worth After Its Latest Results
When Will 2seventy Bio, Inc. (NASDAQ:TSVT) Become Profitable?
2seventy Bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag